MAPT and Alzheimer disease: Biochemical studies indicate the neuroprotective action of EGCG, which has been suggested to inhibit the aggregation of a number of amyloidogenic peptides and proteins effectively, including α-synuclein [31,32,33,34,35], amyloid-β (related to AD) [31,36], islet amyloid polypeptide (related to type-II diabetes) [37,38], huntingtin exon 1 (related to Huntington’s disease) [39], tau (related to AD and tauopathies) [40], superoxide dismutase (related to amyotrophic lateral sclerosis) [41], prion proteins (related to prion diseases) [42,43], and others.